CoChat

Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study

Open access

Published version of a preprint

The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.

Abstract

Although transcatheter arterial chemoembolization (TACE) is the standard of care for intermediate-stage hepatocellular carcinoma (HCC), this is a largely heterogeneous disease that includes a subgroup of patients who do not benefit from TACE. The treatment strategy for this subgroup of patients currently remains an unmet need in clinical practice. Here, we performed a proof-of-concept study that lenvatinib may be a more favorable treatment option over TACE as an initial treatment in intermediate-stage HCC patients with large or multinodular tumours exceeding the up-to-seven criteria. This proof-of-concept study included 642 consecutive patients with HCC initially treated with lenvatinib or conventional TACE (cTACE) between January 2006 and December 2018. Of these patients, 176 who received lenvatinib or cTACE as an initial treatment and met the eligibility criteria (unresectable, beyond the up-to-seven criteria, no prior TACE/systemic therapy, no vascular invasion, no extrahepatic spread and Child–Pugh A liver function) were selected for the study. Propensity score matching was used to adjust for patient demographics. After propensity-score matching, the outcome of 30 patients prospectively treated with lenvatinib (14 in clinical trials, one in an early access program and 15 in real world settings) and 60 patients treated with cTACE as the initial treatment was compared. The change of albumin-bilirubin (ALBI) score from baseline to the end of treatment were −2.61 to −2.61 for 30 patients in the lenvatinib group (p = 0.254) and −2.66 to −2.09 in the cTACE group (p < 0.01), respectively. The lenvatinib group showed a significantly higher objective response rate (73.3% vs. 33.3%; p < 0.001) and significantly longer median progression-free survival than the cTACE group (16.0 vs. 3.0 months; p < 0.001). Overall survival was significantly longer in the lenvatinib group than in the cTACE group (37.9 vs. 21.3 months; hazard ratio: 0.48, p < 0.01). In patients with large or multinodular intermediate-stage HCC exceeding the up-to-seven criteria with Child–Pugh A liver function, who usually do not benefit from TACE, lenvatinib provides a more favorable outcome than TACE.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers11081084

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure A1 Albumin-bilirubin (ALBI) score over time in patients with ALBI grade 1 treated by lenvatinib (n = 19) or TACE (n = 37) (propensity score matching results). ALBI score was significantly worsened at the end of treatment (−2.23) as compared with that at the baseline (−2.93) in TACE treated group (p < 0.01). In contrast, ALBI score was maintained at the baseline (−2.87) and at the end of treatment (−2.74) in the lenvatinib-treated group.
Figure A1 Albumin-bilirubin (ALBI) score over time in patients with ALBI grade 1 treated by lenvatinib (n = 19) or TACE (n = 37) (propensity score matching results). ALBI score was significantly worsened at the end of treatment (−2.23) as compared with that at the baseline (−2.93) in TACE treated group (p < 0.01). In contrast, ALBI score was maintained at the baseline (−2.87) and at the end of treatment (−2.74) in the lenvatinib-treated group.CC BY · PubMed Central
Figure A2 Progression free survival (PFS) in both groups with ALBI grade 1 liver function after propensity score matching. PFS in the lenvatinib-treated group was significantly better than that in the TACE-treated group (16.0 months vs. 3.0 months; HR 0.16, p < 0.001). NR; not reached.
Figure A2 Progression free survival (PFS) in both groups with ALBI grade 1 liver function after propensity score matching. PFS in the lenvatinib-treated group was significantly better than that in the TACE-treated group (16.0 months vs. 3.0 months; HR 0.16, p < 0.001). NR; not reached.CC BY · PubMed Central
Figure A3 Overall survival (OS) in both groups with ALBI grade 1 after propensity score matching. OS in the lenvatinib-treated group was significantly better than that in the TACE-treated group (not reached (NR) vs. 23.1 months; HR 0.27, p = 0.021). NR; not reached.
Figure A3 Overall survival (OS) in both groups with ALBI grade 1 after propensity score matching. OS in the lenvatinib-treated group was significantly better than that in the TACE-treated group (not reached (NR) vs. 23.1 months; HR 0.27, p = 0.021). NR; not reached.CC BY · PubMed Central
Figure 1 Patients enrolled in this study. A total of 642 patients received lenvatinib or TACE as an initial treatment for intermediate stage HCC between 2006 and 2018. Of them, 37 lenvatinib-treated patients and 139 TACE-treated patients met the eligibility criteria of this study, which is patients with Child–Pugh A liver function and tumor burden of beyond up-to-seven criteria. After propensity score matching, efficacy was compared between 30 lenvatinib-treated patients and 60 TACE-treated patients. TACE; transcatheter arterial chemoembolisation. UT7; up to seven
Figure 1 Patients enrolled in this study. A total of 642 patients received lenvatinib or TACE as an initial treatment for intermediate stage HCC between 2006 and 2018. Of them, 37 lenvatinib-treated patients and 139 TACE-treated patients met the eligibility criteria of this study, which is patients with Child–Pugh A liver function and tumor burden of beyond up-to-seven criteria. After propensity score matching, efficacy was compared between 30 lenvatinib-treated patients and 60 TACE-treated patients. TACE; transcatheter arterial chemoembolisation. UT7; up to sevenCC BY · PubMed Central
Figure 2 Albumin-bilirubin (ALBI) score over time in lenvatinib and TACE treated groups. ALBI score was significantly worsened at the end of treatment (−2.09) as compared with that at the baseline (−2.66) in the TACE treated group (p < 0.01). In contrast, ALBI score was maintained at the baseline (−2.61) and at the end of treatment (−2.61) in the lenvatinib-treated group.
Figure 2 Albumin-bilirubin (ALBI) score over time in lenvatinib and TACE treated groups. ALBI score was significantly worsened at the end of treatment (−2.09) as compared with that at the baseline (−2.66) in the TACE treated group (p < 0.01). In contrast, ALBI score was maintained at the baseline (−2.61) and at the end of treatment (−2.61) in the lenvatinib-treated group.CC BY · PubMed Central
Figure 3 Progression free survival (PFS) in both groups with Child–Pugh A liver function after propensity score matching. PFS in the lenvatinib-treated group was significantly better than that in the TACE-treated group (16.0 months vs. 3.0 months; hazard ratio (HR) 0.19, p < 0.001).
Figure 3 Progression free survival (PFS) in both groups with Child–Pugh A liver function after propensity score matching. PFS in the lenvatinib-treated group was significantly better than that in the TACE-treated group (16.0 months vs. 3.0 months; hazard ratio (HR) 0.19, p < 0.001).CC BY · PubMed Central
Figure 4 Overall survival (OS) in both groups after propensity score matching. OS in the lenvatinib-treated group was significantly better than that in the TACE-treated group (37.9 months vs. 21.3 months; hazard ratio (HR)0.48, p < 0.01). NR; not reached
Figure 4 Overall survival (OS) in both groups after propensity score matching. OS in the lenvatinib-treated group was significantly better than that in the TACE-treated group (37.9 months vs. 21.3 months; hazard ratio (HR)0.48, p < 0.01). NR; not reachedCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

See all 309

Metadata

Authors
Kudo, M., Ueshima, K., Chan, S., Minami, T., Chishina, H., Aoki, T., Takita, M., Hagiwara, S., Minami, Y., Ida, H., Takenaka, M., Sakurai, T., Watanabe, T., Morita, M., Ogawa, C., Wada, Y., Ikeda, M., Ishii, H., Izumi, N., & Nishida, N.
Affiliations
  • Kindai University (JP)
  • Chinese University of Hong Kong (HK)
  • Takamatsu Red Cross Hospital (JP)
  • National Kyushu Medical Center (JP)
  • National Cancer Center Hospital East (JP)
  • Chiba Cancer Center (JP)
  • Musashino Red Cross Hospital (JP)
Corresponding author
Kudo, Masatoshi
Venue
Cancers
Publisher
MDPI AG
Published
2019-07-31
Volume
11
Issue
8
Pages
1084
ISSN
2072-6694 (ISSN-L)
OpenAlex
W2953756046
Cited by
309
References
48
Citations by year
2026: 16 · 2025: 34 · 2024: 43 · 2023: 56 · 2022: 62 · 2021: 59 · 2020: 35 · 2019: 2
FWCI
25.19
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • Preprints.org (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Eisai
  • Smoking Research Foundation
  • Kobayashi Foundation for Cancer Research
  • SENSHIN Medical Research Foundation
  • Yakult Bio-Science Foundation
  • Chugai Pharmaceutical
  • Japan Society for the Promotion of Science (18K07922)
Topics
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Keywords
lenvatinib, hepatocellular carcinoma, intermediate-stage HCC, transarterial chemoembolization, up-to-seven criteria, initial treatment, objective response rate, progression-free survival, overall survival, albumin-bilirubin score, real-world evidence, tyrosine kinase inhibitors, unmet medical needs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study. https://app.cochat.ai/papers/10.3390/cancers11081084
The paper
Kudo, M., Ueshima, K., Chan, S., Minami, T., Chishina, H., Aoki, T., Takita, M., Hagiwara, S., Minami, Y., Ida, H., Takenaka, M., Sakurai, T., Watanabe, T., Morita, M., Ogawa, C., Wada, Y., Ikeda, M., Ishii, H., Izumi, N., & Nishida, N. (2019). Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study. Cancers. https://doi.org/10.3390/cancers11081084

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.